Allison C. Hoffman Sells 6,556 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 6,556 shares of the stock in a transaction on Monday, January 27th. The shares were sold at an average price of $27.48, for a total value of $180,158.88. Following the completion of the sale, the general counsel now directly owns 152,361 shares of the company’s stock, valued at $4,186,880.28. The trade was a 4.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Phreesia Price Performance

Shares of NYSE PHR opened at $29.03 on Friday. The firm has a market cap of $1.69 billion, a price-to-earnings ratio of -19.75 and a beta of 0.94. The stock has a fifty day simple moving average of $24.78 and a two-hundred day simple moving average of $23.24. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. Phreesia, Inc. has a 1-year low of $17.07 and a 1-year high of $29.90.

Phreesia (NYSE:PHR) last announced its quarterly earnings data on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.04. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The company had revenue of $106.80 million during the quarter, compared to analyst estimates of $106.33 million. During the same quarter last year, the firm posted ($0.58) EPS. The firm’s revenue for the quarter was up 16.6% on a year-over-year basis. Analysts anticipate that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Hedge Funds Weigh In On Phreesia

Several large investors have recently modified their holdings of the business. R Squared Ltd purchased a new stake in shares of Phreesia during the 4th quarter valued at approximately $30,000. International Assets Investment Management LLC raised its holdings in Phreesia by 2,179.7% during the 3rd quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock valued at $33,000 after acquiring an additional 1,395 shares during the period. XTX Topco Ltd purchased a new stake in shares of Phreesia during the third quarter worth $247,000. Hsbc Holdings PLC bought a new position in shares of Phreesia in the second quarter worth $301,000. Finally, Intech Investment Management LLC purchased a new position in shares of Phreesia in the third quarter valued at $316,000. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on PHR. Robert W. Baird reduced their target price on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Piper Sandler reaffirmed an “overweight” rating and issued a $33.00 price objective (up from $31.00) on shares of Phreesia in a research report on Wednesday. KeyCorp lifted their target price on shares of Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 8th. Citigroup upped their target price on Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a report on Friday, January 10th. Finally, JMP Securities reiterated a “market outperform” rating and set a $30.00 price target on shares of Phreesia in a report on Tuesday, December 10th. Thirteen equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $31.15.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.